BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

327 related articles for article (PubMed ID: 30315258)

  • 21. KRAS and DAXX/ATRX gene mutations are correlated with the clinicopathological features, advanced diseases, and poor prognosis in Chinese patients with pancreatic neuroendocrine tumors.
    Yuan F; Shi M; Ji J; Shi H; Zhou C; Yu Y; Liu B; Zhu Z; Zhang J
    Int J Biol Sci; 2014; 10(9):957-65. PubMed ID: 25210493
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prognostic and Predictive Biomarkers for Pancreatic Neuroendocrine Tumors.
    Hackeng WM; Assi HA; Westerbeke FHM; Brosens LAA; Heaphy CM
    Surg Pathol Clin; 2022 Sep; 15(3):541-554. PubMed ID: 36049835
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Endoscopic ultrasound fine-needle biopsy to assess DAXX/ATRX expression and alternative lengthening of telomeres status in non-functional pancreatic neuroendocrine tumors.
    Mastrosimini MG; Manfrin E; Remo A; De Bellis M; Parisi A; Pedron S; Luchini C; Brunelli M; Ammendola S; Bernardoni L; Conti Bellocchi MC; Gabbrielli A; Facciorusso A; Pea A; Landoni L; Scarpa A; Crinò SF
    Pancreatology; 2023 Jun; 23(4):429-436. PubMed ID: 37169669
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Loss of DAXX and ATRX are associated with chromosome instability and reduced survival of patients with pancreatic neuroendocrine tumors.
    Marinoni I; Kurrer AS; Vassella E; Dettmer M; Rudolph T; Banz V; Hunger F; Pasquinelli S; Speel EJ; Perren A
    Gastroenterology; 2014 Feb; 146(2):453-60.e5. PubMed ID: 24148618
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Altered telomeres in tumors with ATRX and DAXX mutations.
    Heaphy CM; de Wilde RF; Jiao Y; Klein AP; Edil BH; Shi C; Bettegowda C; Rodriguez FJ; Eberhart CG; Hebbar S; Offerhaus GJ; McLendon R; Rasheed BA; He Y; Yan H; Bigner DD; Oba-Shinjo SM; Marie SK; Riggins GJ; Kinzler KW; Vogelstein B; Hruban RH; Maitra A; Papadopoulos N; Meeker AK
    Science; 2011 Jul; 333(6041):425. PubMed ID: 21719641
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Insights into Epigenetic Changes Related to Genetic Variants and Cells-of-Origin of Pancreatic Neuroendocrine Tumors: An Algorithm for Practical Workup.
    Ciobanu OA; Martin SC; Herlea V; Fica S
    Cancers (Basel); 2022 Sep; 14(18):. PubMed ID: 36139607
    [TBL] [Abstract][Full Text] [Related]  

  • 27. New Genetics and Genomic Data on Pancreatic Neuroendocrine Tumors: Implications for Diagnosis, Treatment, and Targeted Therapies.
    Schmitt AM; Marinoni I; Blank A; Perren A
    Endocr Pathol; 2016 Sep; 27(3):200-4. PubMed ID: 27456058
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Multiregion WES of metastatic pancreatic neuroendocrine tumors revealed heterogeneity in genomic alterations, immune microenvironment and evolutionary patterns.
    Jiang Y; Dong YH; Zhao SW; Liu DY; Zhang JY; Xu XY; Chen H; Chen H; Jin JB
    Cell Commun Signal; 2024 Mar; 22(1):164. PubMed ID: 38448900
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Centromeric cohesion failure invokes a conserved choreography of chromosomal mis-segregations in pancreatic neuroendocrine tumor.
    Quevedo R; Spreafico A; Bruce J; Danesh A; El Ghamrasni S; Giesler A; Hanna Y; Have C; Li T; Yang SYC; Zhang T; Asa SL; Haibe-Kains B; Krzyzanowska M; Smith AC; Singh S; Siu LL; Pugh TJ
    Genome Med; 2020 Apr; 12(1):38. PubMed ID: 32345369
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Alternative Lengthening of Telomeres Phenotype Predicts Progression Risk in Noninsulinomas in a Chinese Cohort.
    Ban X; Mo S; Lu Z; Jia C; Shao H; Yan J; Chang X; Mao X; Wu Y; Zhang Y; Fan X; Yu S; Chen J
    Neuroendocrinology; 2022; 112(5):510-522. PubMed ID: 34348341
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Whole-genome sequencing reveals distinct genetic bases for insulinomas and non-functional pancreatic neuroendocrine tumours: leading to a new classification system.
    Hong X; Qiao S; Li F; Wang W; Jiang R; Wu H; Chen H; Liu L; Peng J; Wang J; Jia C; Liang X; Dai H; Jiang J; Zhang T; Liao Q; Dai M; Cong L; Han X; Guo D; Liang Z; Li D; Zheng Z; Ye C; Li S; Zhao Y; Wu K; Wu W
    Gut; 2020 May; 69(5):877-887. PubMed ID: 31462556
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Ileal neuroendocrine tumors show elevated activation of mammalian target of rapamycin complex.
    Geis C; Fendrich V; Rexin P; Di Fazio P; Bartsch DK; Ocker M; Quint K; Heverhagen AE
    J Surg Res; 2015 Apr; 194(2):388-393. PubMed ID: 25439321
    [TBL] [Abstract][Full Text] [Related]  

  • 33. ATRX and DAXX: Mechanisms and Mutations.
    Dyer MA; Qadeer ZA; Valle-Garcia D; Bernstein E
    Cold Spring Harb Perspect Med; 2017 Mar; 7(3):. PubMed ID: 28062559
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Current understanding of the molecular biology of pancreatic neuroendocrine tumors.
    Zhang J; Francois R; Iyer R; Seshadri M; Zajac-Kaye M; Hochwald SN
    J Natl Cancer Inst; 2013 Jul; 105(14):1005-17. PubMed ID: 23840053
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Convergence between germline and somatic mutations in pancreatic neuroendocrine tumors.
    Ling C; Hong X; Xu M; Wang Y; Ma X; Cui Y; Jiang R; Cao D; Wu H; Tong A; Zhao Y; Wu W
    Eur J Endocrinol; 2022 May; 187(1):85-90. PubMed ID: 35521758
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Hotspot DAXX, PTCH2 and CYFIP2 mutations in pancreatic neuroendocrine neoplasms.
    Vandamme T; Beyens M; Boons G; Schepers A; Kamp K; Biermann K; Pauwels P; De Herder WW; Hofland LJ; Peeters M; Van Camp G; Op de Beeck K
    Endocr Relat Cancer; 2019 Jan; 26(1):1-12. PubMed ID: 30021865
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Somatostatin receptor activity assessed by
    Mapelli P; Bezzi C; Muffatti F; Ghezzo S; Baldassi F; Schiavo Lena M; Andreasi V; Canevari C; Magnani P; De Cobelli F; Gianolli L; Partelli S; Falconi M; Picchio M
    Eur J Nucl Med Mol Imaging; 2023 Jul; 50(9):2818-2829. PubMed ID: 37010579
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical implications of cell-of-origin epigenetic characteristics in non-functional pancreatic neuroendocrine tumors.
    Dreijerink KM; Hackeng WM; Singhi AD; Heaphy CM; Brosens LA
    J Pathol; 2022 Feb; 256(2):143-148. PubMed ID: 34750813
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Combined deletion of MEN1, ATRX and PTEN triggers development of high-grade pancreatic neuroendocrine tumors in mice.
    Fuentes ME; Lu X; Flores NM; Hausmann S; Mazur PK
    Sci Rep; 2024 Apr; 14(1):8510. PubMed ID: 38609433
    [TBL] [Abstract][Full Text] [Related]  

  • 40. DNA methylation patterns identify subgroups of pancreatic neuroendocrine tumors with clinical association.
    Lakis V; Lawlor RT; Newell F; Patch AM; Mafficini A; Sadanandam A; Koufariotis LT; Johnston RL; Leonard C; Wood S; Rusev B; Corbo V; Luchini C; Cingarlini S; Landoni L; Salvia R; Milella M; Chang D; Bailey P; Jamieson NB; Duthie F; Gingras MC; Muzny DM; Wheeler DA; Gibbs RA; Milione M; ; ; Pederzoli P; Samra JS; Gill AJ; Johns AL; Pearson JV; Biankin AV; Grimmond SM; Waddell N; Nones K; Scarpa A
    Commun Biol; 2021 Feb; 4(1):155. PubMed ID: 33536587
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.